active immunotherapy

Summary

Summary: Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.

Top Publications

  1. ncbi Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines
    Jorgen Kjaergaard
    Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurosurg 103:156-64. 2005
  2. pmc Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2
    Akiva Mintz
    Brain Tumor Center of Excellence, Department of Neurosurgery and Radiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    Cancer Biother Radiopharm 23:581-9. 2008
  3. ncbi [Study on changes of serum T helper cell type 1 and 2 cytokines after active immunotherapy in women with unexplained habitual abortion]
    L Qiu
    Department of Obstetrics and Gynecology, Renji Hospital of Shanghai Second Medical University, Shanghai 200001, China
    Zhonghua Fu Chan Ke Za Zhi 36:408-10. 2001
  4. ncbi Exploiting dendritic cells for active immunotherapy of cancer and chronic infections
    David W O'Neill
    Pathology, New York University School of Medicine, Rusk Research Bldg, Room 718, 400 East 34th Street, NewYork, NY 10016, USA
    Mol Biotechnol 36:131-41. 2007
  5. ncbi Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma
    Erin Gatza
    Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor 48101, USA
    J Immunol 169:5227-35. 2002
  6. ncbi Active immunotherapy of multiple myeloma
    Leonora Houet
    Department of Haematology Oncology, Freiburg University Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    Eur J Cancer 42:1653-60. 2006
  7. ncbi Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial
    Elia Neninger
    Hermanos Amejeiras Hospital, Havana City, Cuba 10300
    Cancer Biol Ther 6:145-50. 2007
  8. ncbi Assays for monitoring cellular immune responses to active immunotherapy of cancer
    T M Clay
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 7:1127-35. 2001
  9. ncbi Specific active immunotherapy of cancer: potential and perspectives
    Roopa Srinivasan
    Department of Research, CancerVax Corporation, Carlsbad, CA 92008 7328, USA
    Rev Recent Clin Trials 1:283-92. 2006
  10. pmc Heat-shock protein vaccines as active immunotherapy against human gliomas
    Isaac Yang
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Expert Rev Anticancer Ther 9:1577-82. 2009

Detail Information

Publications250 found, 100 shown here

  1. ncbi Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines
    Jorgen Kjaergaard
    Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurosurg 103:156-64. 2005
    ..In this study, the authors tested whether active immunotherapy is curative in mice bearing advanced, rapidly progressive intracranial tumors.
  2. pmc Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2
    Akiva Mintz
    Brain Tumor Center of Excellence, Department of Neurosurgery and Radiology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    Cancer Biother Radiopharm 23:581-9. 2008
    ....
  3. ncbi [Study on changes of serum T helper cell type 1 and 2 cytokines after active immunotherapy in women with unexplained habitual abortion]
    L Qiu
    Department of Obstetrics and Gynecology, Renji Hospital of Shanghai Second Medical University, Shanghai 200001, China
    Zhonghua Fu Chan Ke Za Zhi 36:408-10. 2001
    OBJECTIVE: To investigate the changes of serum T helper cell (TH)1/TH2 type cytokines after the active immunotherapy in unexplained habitual abortion (UHA) women...
  4. ncbi Exploiting dendritic cells for active immunotherapy of cancer and chronic infections
    David W O'Neill
    Pathology, New York University School of Medicine, Rusk Research Bldg, Room 718, 400 East 34th Street, NewYork, NY 10016, USA
    Mol Biotechnol 36:131-41. 2007
    ..This review presents a brief overview of DC biology and of the preparation and use of DC-based vaccines...
  5. ncbi Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma
    Erin Gatza
    Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor 48101, USA
    J Immunol 169:5227-35. 2002
    ....
  6. ncbi Active immunotherapy of multiple myeloma
    Leonora Houet
    Department of Haematology Oncology, Freiburg University Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    Eur J Cancer 42:1653-60. 2006
    Since myeloma cells express various potential target antigens, active immunotherapy is being investigated as a novel treatment modality for myeloma...
  7. ncbi Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial
    Elia Neninger
    Hermanos Amejeiras Hospital, Havana City, Cuba 10300
    Cancer Biol Ther 6:145-50. 2007
    ..A prolonged survival was observed in several patients treated with the anti-idiotype vaccine. No evidence of serious adverse effects was found...
  8. ncbi Assays for monitoring cellular immune responses to active immunotherapy of cancer
    T M Clay
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 7:1127-35. 2001
    ..We provide examples of how each has been used to monitor recent clinical trials and a discussion of how well each correlates with clinical outcome...
  9. ncbi Specific active immunotherapy of cancer: potential and perspectives
    Roopa Srinivasan
    Department of Research, CancerVax Corporation, Carlsbad, CA 92008 7328, USA
    Rev Recent Clin Trials 1:283-92. 2006
    ..This review covers the potential and issues with specific active immunotherapies (SAI) for the treatment of cancer...
  10. pmc Heat-shock protein vaccines as active immunotherapy against human gliomas
    Isaac Yang
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Expert Rev Anticancer Ther 9:1577-82. 2009
    Modern advances in cancer immunotherapy have led to the development of active immunotherapy that utilizes tumor-associated antigens to induce a specific immune response against the tumor...
  11. ncbi CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases
    Federico Perosa
    Department of Internal Medicine and Clinical Oncology DIMO, University of Bari Medical School, Piazza Giulio Cesare 11, 70124 Bari, Italy
    Ann N Y Acad Sci 1051:672-83. 2005
    ..This peptide is currently being investigated to determine the effectiveness of CD20-based active IT for the treatment of autoimmune diseases...
  12. pmc Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors
    Nicolas Larmonier
    Department of Pediatrics, Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    J Immunol 181:6955-63. 2008
    ..The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy...
  13. ncbi Tumors as elusive targets of T-cell-based active immunotherapy
    Francesco M Marincola
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Trends Immunol 24:335-42. 2003
    ..Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization...
  14. ncbi Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    Eddy C Hsueh
    Sonya Valley Ghidossi Vaccine Laboratory, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 20:4549-54. 2002
    ..Because melanoma is immunogenic, we investigated whether a therapeutic cancer vaccine called Canvaxin (CancerVax Corporation, Carlsbad, CA) could enhance antitumor immune responses and thereby prolong survival...
  15. ncbi Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
    Matteo Bellone
    Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy
    Trends Immunol 29:235-41. 2008
    ..This approach has the potential to empower chemoimmunotherapeutic strategies by improving cytotoxic drug penetration into tumors while exploiting the proinflammatory and immunostimulating activities of TNF-alpha and active immunotherapy.
  16. ncbi Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
    N C Fox
    Dementia Research Centre, Institute of Neurology, London, UK
    Neurology 64:1563-72. 2005
    ..Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients...
  17. ncbi Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha
    Ulka Vaishampayan
    Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:3696-701. 2002
    ..In this Phase II trial, the combination of cyclophosphamide, Melacine, and IFNalpha was tested in metastatic malignant melanoma...
  18. ncbi Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study
    E Ovali
    Karadeniz Technical University, Department of Haematology, Trabzon, Turkey
    J Exp Clin Cancer Res 26:209-14. 2007
    ..01). The results showed that this active immunotherapy is feasible, safe, and may be capable of eliciting immune responses against cancer.
  19. ncbi Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer
    Ekaterina V Moiseeva
    Shemyakin Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluklio Maklaya St 16 10, 117871, Moscow V437, Russia
    Cancer Immunol Immunother 52:487-96. 2003
    ..Advanced relatively fast i.p and s.c. growing mammary carcinomas seem to be more sensitive to a single IL-2 treatment than relatively slowly growing tumours. IL-2 was most effective against non-metastasised mouse breast cancer...
  20. ncbi Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma
    D L Morton
    The Sonya Valley Ghidossi Vaccine Laboratory, Roy E Coats Research Laboratories, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Dev Biol (Basel) 116:209-17; discussion 229-36. 2004
    ..melanoma depends in part on the patient's immune response, which can be modulated by post-operative active immunotherapy with Canvaxin therapeutic polyvalent cancer vaccine (CancerVax Corp., Carlsbad, CA)...
  21. ncbi Exploiting dendritic cells for active immunotherapy of cancer and chronic infection
    David O'Neill
    Tumor Vaccine Center, NYU Cancer Institute, New York University School of Medicine, New York, NY, USA
    Methods Mol Med 109:1-18. 2005
    ..This chapter presents a brief overview of DC biology and the preparation and use of DC-based vaccines...
  22. ncbi Targets for active immunotherapy against pediatric solid tumors
    J F M Jacobs
    Department of Pediatric Hemato Oncology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Cancer Immunol Immunother 58:831-41. 2009
    ..In this review we discuss the current status of cancer immunotherapy in children, focusing on the identification of tumor-specific antigens on pediatric solid tumors...
  23. ncbi Manipulating dendritic cell biology for the active immunotherapy of cancer
    David W O'Neill
    New York University School of Medicine, 550 1st Ave, MSB 507, New York, NY 10016, USA
    Blood 104:2235-46. 2004
    ..This review discusses recent advances in DC research and the application of this knowledge toward new strategies for the clinical manipulation of DCs for cancer immunotherapy...
  24. ncbi A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 5:1331-8. 1999
    ..We conclude that it is feasible and safe to generate and administer large numbers of previously cryopreserved DCs loaded with CAP-1 peptide to patients with advanced malignancies...
  25. pmc Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
    Donald L Morton
    John Wayne Center Institute, Santa Monica, CA 90404, USA
    Ann Surg 236:438-48; discussion 448-9. 2002
    ....
  26. ncbi Translational development of active immunotherapy for hematologic malignancies
    Larry W Kwak
    National Institutes of Health, Frederick, MD 21702 1201, USA
    Semin Oncol 30:17-22. 2003
    ..This pivotal study is the final step before vaccine therapy might be considered as an option of standard care for patients with follicular lymphoma...
  27. ncbi Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
    M A Steller
    Section of Gynecologic Oncology, Surgery Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 4:2103-9. 1998
    ..Although enhancements of cellular immune responses are needed to achieve therapeutic utility in advanced cervical cancer, this approach might prove useful in treating preinvasive disease...
  28. ncbi Vaccine therapy for cutaneous T-cell lymphoma
    Naohiro Seo
    Department of Dermatology, Hamamatsu University School of Medicine, 1 20 1 Handa yama, Hamamatsu, Shizuoka 431 3192, Japan
    Hematol Oncol Clin North Am 17:1467-74. 2003
    ..The effective induction of CTLs suggests that the method that uses barrier-disrupted skin can potentially be applied to treatments of virus and helminth infections with the use of certain antigenic peptides...
  29. ncbi Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats
    Shuzi Zhang
    Vaccine Research Center, College of Life Science, Jilin University, Changchun, People s Republic of China
    Hum Immunol 69:250-8. 2008
    ..The combination of the MUC1 VNTR DNA vaccine and the IL-2 adjuvant plasmid provides an attractive alternative for prophylactic and therapeutic vaccinations against MUC1(+) tumors...
  30. pmc Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 15:1176-83. 2008
    ..The clinical implications of the current study are discussed...
  31. ncbi Cancer vaccines: a critical review on clinical impact
    Roberto J Bitton
    Novartis Oncology, Medical Department, Ramallo 1851, 3rd floor CP1429, Buenos Aires, Argentina
    Curr Opin Mol Ther 6:17-26. 2004
    ..Most of the vaccines are still experimental, far from being approved by regulatory authorities, and their clinical utility is almost negligible...
  32. ncbi Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism
    W F Cheng
    Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
    Gene Ther 15:1007-16. 2008
    ..By prolonging the survival of APCs, DNA vaccine encoding CTGF linked to a tumor antigen represents an innovative approach to enhance DNA vaccine potency and holds promise for cancer prophylaxis and immunotherapy...
  33. ncbi Immunobiology and gene-based immunotherapy of hepatocellular carcinoma
    M Geissler
    Department of Medicine II, University Hospital Freiburg, Freiburg, Germany
    Z Gastroenterol 41:1101-10. 2003
    ..Novel therapeutic strategies and a better understanding of HCC imunobiology are, therefore, urgently required...
  34. ncbi Alphavirus vectors for vaccine production and gene therapy
    Kenneth Lundstrom
    Regulon Inc, Epalinges, Switzerland
    Expert Rev Vaccines 2:447-59. 2003
    ....
  35. ncbi Preparation of peptide-loaded dendritic cells for cancer immunotherapy
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Mol Biotechnol 25:95-9. 2003
    ..We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy...
  36. pmc High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
    David Alexandre Gross
    Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 113:425-33. 2004
    ..Our results strongly argue for new TAA epitope selection and modification strategies in antitumor immunotherapy applications in humans...
  37. ncbi Autologous soluble tumor-associated antigens prevent the toxic side effects of cancer chemotherapy and inhibit the progress of tumorigenesis: case report
    Herzl Ben-Hur
    Laboratory of Experimental Medicine, Park Rabin, Rehovot, Israel
    Oncol Rep 10:2059-61. 2003
    ..We suggest that immunotherapy with autologous sTAA provides significant clinical benefits in cancer patients and appears to be an important new adjuvant treatment of cancer...
  38. ncbi Cancer vaccines
    V F Chekhun
    Exp Oncol 30:90. 2008
  39. ncbi [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]
    Fabrice Benchetrit
    Unité d Immunologie Cellulaire et Clinique, INSERM U 255, Universite Pierre et Marie Curie, Centre de recherches biomédicales des Cordeliers 15, rue de l Ecole de Medecine, 75270 Paris, France
    Bull Cancer 90:677-85. 2003
    ..To circumvent these tumor escape mechanisms, efficient cancer vaccines will have to recruit CD8+ T cells associated with other immune effectors...
  40. ncbi Part I: Vaccines for solid tumours
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Italy
    Lancet Oncol 5:681-9. 2004
    ....
  41. ncbi Vaccine and antibody-directed T cell tumour immunotherapy
    Said Dermime
    Immunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Biochim Biophys Acta 1704:11-35. 2004
    ....
  42. ncbi Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine
    Ji Yan Liu
    State Key Laboratory of Oncology in South China and Department of Biotherapy, Sun Yat sen University Cancer Center, Guangzhou, and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan, Guangdong, People s Republic of China
    Cancer Immunol Immunother 56:1597-604. 2007
    ..Our results suggested a possible mechanism of CTX-induced immunopotentiation and provided a strategy of immunotherapy combining a low dose CTX with DC vaccine...
  43. ncbi In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients
    Zuzana Tobiasova
    Department of Immunology, Charles University, 2nd Medical School and Faculty Hospital Motol, V Uvalu 84, 150 06 Praha 5, Prague, Czech Republic
    Clin Immunol 122:18-27. 2007
    ..Lymphocyte IFN-gamma production increased in response to tumor antigen-pulsed DC. We show the feasibility of preparing individual DC-based vaccines in ovarian cancer patients and the potential for induction of lymphocyte responses...
  44. ncbi Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated
    Richard Harrop
    Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, OX4 4GA, Oxford, UK
    Cancer Immunol Immunother 55:1081-90. 2006
    ..Thus, we conclude that CD4+ T cells are essential for the induction of a protective immune response and that antibodies are the likely effector moiety in this xenogeneic murine tumor model...
  45. pmc Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
    Kang Liu
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 202:1507-16. 2005
    ..Therefore, the access of dying tumor cells to DCs that are maturing to activated NKT cells efficiently induces long-lived adaptive resistance...
  46. ncbi Cancer-testis antigens in haematological malignancies
    Farouk Meklat
    Cancer Research Program, Harrington Regional Medical Center, Amarillo, TX, USA
    Br J Haematol 136:769-76. 2007
    ..Finally, we discuss the direction of future research in advancing the development of tumour vaccines for haematological malignancies...
  47. ncbi Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
    Salem Chouaib
    INSERM U487 Immunologie des tumeurs Humaines, Institut Gustave Roussy, Villejuif, France
    Tunis Med 83:7-10. 2005
  48. ncbi DNA vaccines: successes and limitations in cancer and infectious disease
    Devin B Lowe
    Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, 79430, USA
    J Cell Biochem 98:235-42. 2006
    ..However, many obstacles still face its use in prophylactic and therapeutic vaccination scenarios. The nature of these difficulties alongside the successes and future of plasmid DNA will be discussed...
  49. ncbi Current state and perspectives of dendritic cell vaccination in cancer immunotherapy
    A Farkas
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Skin Pharmacol Physiol 19:124-31. 2006
    ..This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination...
  50. ncbi [Cancer immunotherapy--current status]
    T M Kundig
    Arbeitsgruppe für Experimentelle Immuntherapie, Zurich
    Ther Umsch 63:262-6. 2006
    ..The logical next step is therefore to develop strategies for active immunotherapy, i.e. "vaccines against cancer"...
  51. ncbi Biomarkers for the development of cancer vaccines: current status
    John Copier
    Department of Oncology, Division of Cellular and Molecular Medicine, St George s University of London, London, UK
    Mol Diagn Ther 10:337-43. 2006
    ..The generation of such biomarkers will allow us to make clinical decisions about patient treatment at an earlier stage and should aid in shortening the development time for vaccines...
  52. ncbi Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice
    Karsten Mahnke
    Department of Dermatology, University of Heidelberg, Heidelberg, Germany
    Cancer Res 65:7007-12. 2005
    ..Thus, these data show that targeting of dendritic cells in situ by the means of antibody-antigen conjugates may be a novel way to induce long-lasting antitumor immunity...
  53. ncbi Cancer vaccines: a promising cancer therapy against all odds
    Ann Willman Silk
    School of Medicine, Office of Medical Education, University of Pittsburgh, M 211 Scaife Hall, Pittsburgh, PA 15261, USA
    Future Oncol 3:299-306. 2007
    ..At the very least, it should be given primary consideration in situations where the role of cytotoxic chemotherapy is equivocal and patients are in need of a nontoxic alternative...
  54. ncbi [Vaccination therapy of melanoma]
    Beatrice Schuler-Thurner
    Dermatologische Klinik mit Poliklink, Universitatsklinikum Erlangen
    J Dtsch Dermatol Ges 3:630-45. 2005
  55. ncbi Using antibodies in tumour immunotherapy
    Birgit C Schultes
    Unither Pharmaceuticals, 15 Walnut Street, Suite 300, Wellesley, MA 02481, USA
    Expert Opin Biol Ther 4:1265-84. 2004
    ....
  56. ncbi The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
    Mark Shackleton
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:9. 2004
    ..FL treatment of melanoma patients has pleiotropic clinical and hematological effects. In vivo maturation of FL-generated DCs using imiquimod may increase immune responses to tumor antigens...
  57. ncbi Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells
    Steven De Vleeschouwer
    Department of Neurosurgery, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Childs Nerv Syst 21:7-18. 2005
    ..Dendritic cell vaccination is situated in the diversity of other immunotherapeutical approaches. FURTHER DISCUSSION: Future directions, challenges, and drawbacks will be discussed...
  58. ncbi Immunological monitoring of cancer vaccine therapy
    Dirk Nagorsen
    Charite, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Biol Ther 4:1677-84. 2004
    ....
  59. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
  60. ncbi An MVA vaccine overcomes tolerance to human p53 in mice and humans
    Guang Yun Song
    Department of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, CA, USA
    Cancer Immunol Immunother 56:1193-205. 2007
    ..These mice, referred to as Hupki, were evaluated as a tolerant model to explore the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors...
  61. pmc Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope
    C H Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 12:1180-6. 2005
    ..Our data indicate that a DNA vaccine encoding a SCT can lead to stable enhanced MHC class I presentation of encoded antigenic peptide and may be useful for improving DNA vaccine potency to control tumors or infectious diseases...
  62. ncbi [Active immunotherapy of prostate cancer with a focus on dendritic cells]
    A K Thomas-Kaskel
    Departamento de Medicina Interna I Hematología Oncología y Comprehensive Cancer Center, Freiburg University Medical Center, Freiburg, Alemania, Germany
    Actas Urol Esp 31:668-79. 2007
    ..Close to 1000 prostate cancer patients have been treated with DC-based or other forms of active immunotherapy to date...
  63. ncbi The contenders. Vaccines and viruses take aim at cancer cells
    Frank Clancy
    Minn Med 88:24-8. 2005
  64. ncbi Cell technologies in immunotherapy of cancer
    Vladimir Moiseyenko
    Prof N N Petrov Research Institute of Oncology, Department of Biotherapy and Bone Marrow Transplantation, Saint Petersburg, Russia
    Adv Exp Med Biol 601:387-93. 2007
    ..Vaccine prepared from tumor cell-activated DC bone marrow precursors was administered to 18 patients (clinical results: 2 MR and 6 SD)...
  65. ncbi Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:1555-60. 2006
    ..IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients...
  66. ncbi Towards patient-specific tumor antigen selection for vaccination
    Hans Georg Rammensee
    Department of Immunology, Institute for Cell Biology, University of Tubingen, Tubingen, Germany
    Immunol Rev 188:164-76. 2002
    ..The scope of the present review is to explore the possibilities and the formidable technical and logistical challenge for such individual patient-oriented antigen definition to be used for therapeutic immunization...
  67. ncbi [Cancer immunotherapy. A future therapeutical choice?]
    L Bertolaccini
    Cattedra di Chirurgia d Urgenza e di Pronto Soccorso, Universita degli Studi, Turin, Italy
    Minerva Chir 56:183-91. 2001
    ..Specific active immunotherapy is based on the principle that neoplasm cells contain immunogenic sites against which an antitumoral immune ..
  68. ncbi The use of HLA class I tetramers to design a vaccination strategy for melanoma patients
    Michael Palmowski
    Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Immunol Rev 188:155-63. 2002
    ..These results provide important pointers for future vaccination trials, and tetramers will form an important tool in the immunomonitoring of these clinical studies...
  69. ncbi Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma
    Pedro Romero
    Division of Clinical Onco Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital CHUV, Lausanne, Switzerland
    Immunol Rev 188:81-96. 2002
    ....
  70. ncbi Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
    Pierre G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    Immunol Rev 188:33-42. 2002
    ..In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide...
  71. ncbi Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
    Immunol Rev 188:22-32. 2002
    ..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress...
  72. ncbi Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines
    Bo Dupont
    Memorial Sloan Kettering Cancer Center1275 York Avenue, New York, NY 10021, USA
    Immunol Rev 188:5-8. 2002
  73. ncbi Vaccination for malignant melanoma: recent developments
    D Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt am Main, Deutschland
    Oncology 60:1-7. 2001
    ..Based on these results, active immunotherapy with tumor-associated antigens may be a promising approach for patients in adjuvant treatment situations, ..
  74. ncbi Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
    C F Hung
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer Res 61:1080-8. 2001
    ..These results indicate that fusion of a gene encoding the extracellular domain of FL to an antigen gene may greatly enhance the potency of DNA vaccines via CD8-dependent pathways...
  75. pmc Generation of dendritic cell-based vaccines for cancer therapy
    G Reinhard
    Klinik und Poliklinik für Dermatologie der Rheinischen Friedrich Wilhelms Universität Bonn, Germany
    Br J Cancer 86:1529-33. 2002
    ..Here we discuss various conditions, which are important during generation and administration of dendritic cells to elicit a tumouricidal T cell-based immune response...
  76. ncbi Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction
    I Miconnet
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Switzerland
    J Immunol 166:4612-9. 2001
    ..Thus, the recombinant bacterial protein P40 functions as a potent immunological adjuvant for specific CTL induction...
  77. ncbi Prostate cancer gene therapy
    F A Ferrer
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA
    Hematol Oncol Clin North Am 15:497-508. 2001
    ....
  78. ncbi [Immunotherapy: new insights]
    M Geissler
    Abteilung Innere Medizin II, Medizinische Universitatsklinik Freiburg
    Praxis (Bern 1994) 91:2236-46. 2002
    ..Finally, the identification of antigen specific T and B cells by new assessment tools may result in novel surrogate markers for clinical diagnostic immunotherapy...
  79. ncbi Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules
    Michal Smahel
    Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic
    Vaccine 21:1125-36. 2003
    ..Cell lines with downregulated MHC class I expression derived from TC-1 cells may represent a useful model for testing therapeutic anti-HPV vaccines in settings more relevant to clinical requirements...
  80. ncbi Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21
    T Yamano
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Cancer Gene Ther 14:451-9. 2007
    ..The study demonstrated that CCL21 administration before cTERT DNA vaccination significantly augmented tumor antigen-specific immunity against breast cancer...
  81. ncbi Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters
    M Sherritt
    Tumour Immunology Laboratory, Epstein-Barr Virus Unit, Queensland Institute of Medical Research and University of Queensland Joint Oncology Program, Bancroft Centre, 300 Herston Road, Brisbane, Queensland 4029, Australia
    Int Immunol 13:265-71. 2001
    ..These observations provide a new strategy in anti-cancer vaccine design that allows activation of a highly effective and well-defined CTL response against tumors with down-regulated expression of TAP and MHC class I antigens...
  82. ncbi Immunologic mechanisms of antitumor activity
    Francine M Foss
    Experimental Therapeutics, Tufts New England Medical Center, Boston, MA 02111, USA
    Semin Oncol 29:5-11. 2002
    ....
  83. ncbi Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes
    Cornelis J M Melief
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Immunol Rev 188:177-82. 2002
    ..The recently acquired insights into antigen presentation and costimulatory signals have made possible the development of a new generation of therapeutic anticancer vaccines...
  84. ncbi Monoclonal antibodies in the prehybridoma era: a brief historical perspective and personal reminiscence
    M J Stone
    Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Lymphoma 2:148-54. 2001
    ..It is likely that this approach, alone and in combination with other modalities, will prove useful for patients with additional types of malignancies...
  85. ncbi Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection
    Bunyamin Dikici
    Department of Pediatric Gastroenterology, Dicle University Medical Faculty, Diyarbakir, Turkey
    J Gastroenterol Hepatol 18:218-22. 2003
    The aim of this study was to investigate the efficacy of specific hepatitis B virus (HBV) vaccination as active immunotherapy in treating chronic hepatitis B (CHB) infection during the immune-tolerant phase in children with normal ..
  86. ncbi Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells
    H Bohlen
    Klinik I fur Innere Medizin, Universitat zu Koln, Germany
    Cancer Res 57:1704-9. 1997
    ..J. Exp. Med., 177: 845-850, 1993). This combination of antibodies may therefore be useful for active immunotherapy of malignant tumors...
  87. ncbi Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial)
    V Majumder
    School of Tropical Medicine, Calcutta, India
    Int J Lepr Other Mycobact Dis 64:26-36. 1996
    ....
  88. ncbi Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy
    H Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA
    Cancer Gene Ther 7:486-94. 2000
    ..These data demonstrate the suitability of the TFG-hIL4-Neo-Tk vector for therapeutic studies of cytokine-transduced autologous tumor vaccination in patients with malignant gliomas...
  89. ncbi Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine
    Andrew T Parsa
    Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    J Neurooncol 64:77-87. 2003
    ..In this study we describe an in vitro model of active immunotherapy using autologous fibroblasts as immunogen...
  90. ncbi Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy
    Yuji Ueda
    Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kawaramachi Hirokoji, Kamigyo ku, Kyoto 602 8566, Japan
    Cancer Immunol Immunother 56:381-9. 2007
    ..DCs generated in this fashion were pulsed with HLA-A24-restricted CEA epitope peptide and administered to patients safely; immunological responses were induced in some patients...
  91. ncbi Vaccine therapy in patients with renal cell carcinoma
    Hein Van Poppel
    Department of Urology, University Hospital, KU Leuven, Leuven, Belgium
    Eur Urol 55:1333-42. 2009
    ..Renal cell carcinoma (RCC) is one of the most immunoresponsive cancers in humans. Although immunotherapy is currently much less used than in the past, it remains an important option that warrants further exploration...
  92. ncbi Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma
    E Zhuravel
    R E Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
    Exp Oncol 32:33-9. 2010
    ..To analyze antitumor efficacy of experimental cancer vaccine therapy combined with introduction of vitamin D3 (VD3) for treatment of Lewis lung carcinoma (3LL)...
  93. ncbi Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer
    Uri Galili
    Division of Hematology Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, LRB, Worcester, MA 01605, USA
    Cancer Immunol Immunother 53:935-45. 2004
    ..These residual tumor cells can not be detected by imaging, but their destruction may be feasible by active immunotherapy. Since specific tumor-associated antigens (TAAs) have not been identified for the majority of cancers, ..
  94. ncbi Characterization of polyvalent allogeneic vaccines
    D Van Epps
    CancerVax Corporation, Carlsbad, CA 92008, USA
    Dev Biol (Basel) 116:79-90; discussion 133-43. 2004
    ..Canvaxin is an example of a multi-cell allogeneic, polyvalent active immunotherapy and has been extensively tested in phase I and II clinical trials...
  95. ncbi Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides
    S von Mensdorff-Pouilly
    Department of Obstetrics and Gynaecology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Int J Cancer 86:702-12. 2000
    ..specificity of natural and induced MUC1 Abs with the objective of defining an effective MUC1 vaccine for active immunotherapy of adenocarcinoma patients...
  96. ncbi A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1
    Kwong Yok Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:2139-49. 2004
    ....
  97. ncbi Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters
    Maria Teresa Lizaso
    Department of Allergy, Hospital Virgen del Camino, Pamplona, Spain
    Pediatr Allergy Immunol 19:76-81. 2008
    ..The patients were randomized to the active immunotherapy or placebo group, and a conventional schedule of immunotherapy was used...
  98. ncbi Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy
    T Bucky Jones
    The Neuroscience Graduate Studies Program, School of Allied Medical Professions, The Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210, USA
    J Neurosci 22:2690-700. 2002
    ..Consequently, the safe implementation of such therapies requires that future studies define the mechanisms that control T-cell function within the injured CNS...
  99. ncbi Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy
    Jay S Pepose
    Pepose Vision Institute, 16216 Baxter Road, Ste 205, Chesterfield, MO 63107, USA
    Am J Ophthalmol 141:547-557. 2006
    ..To review the changing epidemiology of herpes simplex virus infection, emerging patterns of herpetic ocular disease, and the challenges and promise of herpes simplex virus vaccine therapy...
  100. ncbi Potent synergistic effect of sho-saiko-to, a herbal medicine, during vaccine therapy in a murine model of hepatitis B virus carrier
    S M Akbar
    Third Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
    Eur J Clin Invest 29:786-92. 1999
    ..The study presented here considers the impact of a combination of vaccine therapy and TJ-9 and the mechanism underlying the therapeutic effect of TJ-9...
  101. pmc Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
    Howard L Kaufman
    The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 5:60. 2007
    ....

Research Grants65

  1. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2003
    ..that CD4+, HLA class II-dependent helper T (TH) cells play in the control of tumor growth, approaches to active immunotherapy with TH cell-defined antigens need to be developed...
  2. Mechanistic study of the host defense functions of IL-32 in tuberculosis
    Edward D Chan; Fiscal Year: 2013
    ..Additionally, enhancing the bioactivity of IL-32 should increase induction of PCD and MTB killing. ..
  3. Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery
    ALISON ANNE MCCORMICK; Fiscal Year: 2010
    ..Unlike current therapies, custom vaccines are easily made, and may facilitate widespread adoption of individualized patient immunotherapy. ..
  4. Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors
    PRAVIN T P contact KAUMAYA; Fiscal Year: 2010
    ..The advantage of active immunotherapy with safe and non toxic natural synthetic peptides over passive immunotherapy with mAbs such as trastuzumab ..
  5. Skin Homing T Cells -- Molecular Characterization of CLA
    Thomas S Kupper; Fiscal Year: 2012
    ..Knowledge generated from this grant application over the next five years will have a significant impact on both areas. ..
  6. Quality and location of presented Ag as determinants of tumor-specific immunity
    Victor H Engelhard; Fiscal Year: 2012
    ..locations, suggesting that homing receptor programming is an important determinant of the effectiveness of active immunotherapy. These two important sets of observations serve as the basis for this renewal application...
  7. Preclinical Development of a Novel and Powerful Immunotherapeutic
    Susan Dana Jones; Fiscal Year: 2013
    ..function, we expect this product will provide a breakthrough that may finally unlock the potential of active immunotherapy for a wide variety of cancers and chronic infectious disease...
  8. B7H1 Mediated Immunosuppression in Glioma
    Andrew T Parsa; Fiscal Year: 2013
    ..The availability of drugs that inhibit the PI(3)K pathway or block B7-H1 and its receptor PD-1 provides a natural extension of these studies into the realm of patient care. ..
  9. Promoting Tumor Immunity by Cross-Linking B7-DC
    Larry R Pease; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): A principal goal of active immunotherapy is to mobilize the immune response against cancer. The ability of host immunity to recognize and destroy tumor cells is well established...
  10. Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
    George Coukos; Fiscal Year: 2012
    ..Aim 2) Assess the safety, feasibility and clinical effects of vaccine and combinatorial immunotherapy. Aim 3) Assess the immune effects of vaccine and combinatorial immunotherapy in the periphery and at the tumor microenvironment. ..
  11. Active Immunity Targeted at PCSK9 for the Treatment of Hypercholesterolemia
    Ba Bie Teng; Fiscal Year: 2012
    ..In this application, we propose to use an active immunotherapy strategy by generating a vaccine that stimulates the immune system against PCSK9...
  12. Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
    Sattva S Neelapu; Fiscal Year: 2010
    ..This award would allow him to focus 75% of his effort to career development and the proposed research. Active immunotherapy is a promising approach for the treatment of B-cell non-Hodgkin's lymphoma...
  13. Role of IDO in Malignancy
    David H Munn; Fiscal Year: 2013
    ..drug 1-methyl-D-tryptophan (1MT), now in Phase I clinical trials, in combination with chemotherapy and active immunotherapy. Aim 1 will test the hypothesis that the highly suppressive Tregs in tumor-draining lymph nodes (TDLNs) can ..
  14. Mechanisms of HSK amelioration
    Patrick M Stuart; Fiscal Year: 2013
    ..Furthermore, these studies could possibly suggest more effective immunotherapies designed to ameliorate human HSK disease. ..
  15. M. D. Anderson Cancer Center SPORE in Multiple Myeloma
    ROBERT ZYGMUNT ORLOWSKI; Fiscal Year: 2013
    ..abstract_text> ..
  16. B7-H1 mediated immunosuppression in immunocompetent animal model of gliomas
    AARON JOHN CLARK; Fiscal Year: 2013
    ..We will determine if B7-H1 expression by GL261 tumor cells induces local immunoresistance that affects tumor growth, immunologic tumor microenvironment, and response to vaccine therapy. ..
  17. SURGERY, IMMUNOLOGY AND IMMUNOTHERAPY OF HUMAN CANCER
    Donald L Morton; Fiscal Year: 2010
    ..for this renewal which will build on the past successes of this program by utilizing both adoptive and active immunotherapy and targeted vaccine designs to induce antigen specific immune responses...
  18. MONOCLONAL ANTIBODIES FOR THE STUDY OF P. CARINII
    Francis Gigliotti; Fiscal Year: 2009
    ..carinii host-parasite interactions. We are particularly interested in utilizing passive and active immunotherapy to prevent or treat P. carinii pneumonia (Pcp)...
  19. SPORE in Head and Neck Cancer
    David Sidransky; Fiscal Year: 2013
    ..Rosner) The Career Development Program(Dr. Sidransky) aids the emergence of new investigators and the Research Developmental Program (Dr. David Sidransky) provides rapid funding of innovative directions. ..
  20. Novel Adjuvant Discovery in Vaccine Therapy
    Govind Ragupathi; Fiscal Year: 2013
    ..These efforts will address fundamental chemical and immunological questions associated with this extremely complex class of adjuvants, and holds the promise of yielding novel therapeutics in the vaccine arena. ..
  21. Bastyr/UW Oncomycology Translational Research Center
    Leanna J Standish; Fiscal Year: 2013
    ..We will investigate the effect of oral doses of PSK, a T. versicolor extract prescribed in Japan as a cancer drug, in augmenting the anticancer immune response in advanced breast cancer. ..
  22. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2000
    ..that CD4+, HLA class II-dependent helper T (TH) cells play in the control of tumor growth, approaches to active immunotherapy with TH cell-defined antigens need to be developed...
  23. TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING A
    FRANK R JONES; Fiscal Year: 2011
    ..processes and studies will allow us to produce sufficient product to support large-scale clinical trials required to move toward approval of this new biotherapeutic for active immunotherapy of CEA expressing cancers.
  24. ANTIIDIOTYPE VACCINE THERAPY OF HUMAN COLORECTAL CANCER
    MALAYA CHATTERJEE; Fiscal Year: 2002
    ..These studies will be a prelude to clinical trials for CRC patients with autologous DC based anti-Id vaccine and scFv. ..
  25. Lamina Propria Antigen Acquisition Pathways and Outcomes
    Rodney D Newberry; Fiscal Year: 2013
    ..This study will investigate a novel mechanism for maintaining the balance between immunity and tolerance and will offer new avenues to pursue for improved mucosal vaccine therapy and chronic intestinal inflammation. ..
  26. CANCER PATIENTS IMMUNE RESPONSES STUDIED IN SCID MICE
    Dorothee Herlyn; Fiscal Year: 1992
    ..To establish a model of active immunotherapy of cancer in SCID mice, we will first optimize reconstitution of the mice with human peripheral blood ..
  27. PROSTATE CANCER GENE THERAPY WITH RECOMBINANT VACCINES
    Martin Sanda; Fiscal Year: 1999
    ..These studies aim to provide a framework for the eventual development and clinical application of recombinant viral vaccines targeting human prostatic antigens in the setting of androgen deprivation therapy. ..
  28. Developement of an alphavirus vaccine for melanoma
    Gerald Donovan; Fiscal Year: 2007
    ..Success in the project would represent an important advance to this field and provide strong impetus for developing TYR-VRP for human testing. [unreadable] [unreadable] [unreadable]..
  29. ACTIVE IMMUNOTHERAPY FOR GLIOBLASTOMA
    John Yu; Fiscal Year: 2004
    ..A phase II trial will be initiated in year 3 of the training grant based on the phase I studies. ..
  30. SPECIFIC ACTIVE IMMUNOTHERAPY OF HUMAN MELANOMA
    Malcolm Mitchell; Fiscal Year: 1993
    The goal of this proposal is to optimize specific active immunotherapy for melanoma...
  31. Targeted antigen receptor treatment of cancer
    David Scheinberg; Fiscal Year: 2009
    ..Two strategies for therapy are explored active immunotherapy (vaccines) to generate antibody and T-cell responses and passive immunotherapy with antibodies (monoclonal ..
  32. New Approaches to Prevent or Treat Breast Cancer Metastases
    Claudia Gravekamp; Fiscal Year: 2009
    ....
  33. NEW MODALITIES FOR ACTIVE IMMUNOTHERAPY OF MALIGNANCIES
    Thomas Kipps; Fiscal Year: 1993
    ..stimulate syngeneic Ig V gene-directed cytolytic T cells lines (CTL) in vitro; 3) investigate modalities of active immunotherapy for a transplantable murine B cell hybridoma expressing rheumatoid factor (RF) encoded by murine Ig ..
  34. Phase 1b Active Immunotherapy with HER-2 Multi-epitope v
    Pravin Kaumaya; Fiscal Year: 2003
    ..abstract_text> ..
  35. IMMUNOTHERAPY OF CHILDHOOD ASTHMA
    N Adkinson; Fiscal Year: 1993
    ..a period of medication stabilization and baseline observations, each is randomized to receive placebo or active immunotherapy with aqueous extracts of pertinent environmental allergens...
  36. IDIOTYPE APPROACH TO THERAPY OF HUMAN T CELL LEUKEMIA
    MALAYA CHATTERJEE; Fiscal Year: 1991
    ....
  37. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 1999
    ..Project 3 (Kipps PI) examines novel techniques for active immunotherapy of this disease, including those involving gene transfer and/or leukemia-purged autologous stem cell ..
  38. CLINICAL TRIAL OF ANTIID VACCINE FOR NEUROBLASTOMA
    Alice Yu; Fiscal Year: 1999
    ..In this application, the applicant plans to explore the role of active immunotherapy with an anti-Id vaccine, Mab 1A7, directed against anti-GD2 in neuroblastoma...
  39. Chemokine Potential in Cancer Immunotherapy
    Dean Johnston; Fiscal Year: 2002
    ..Chemokines that prove effective in these models could be directly translated to clinical trials under the direction of Dr. Jean-Claude Bystryn, the CoPI, at NYU Medical Center. ..
  40. ACTIVE TUMOR IMMUNOTHERAPY TARGETING THE VEGF RECEPTOR
    Yiwen Li; Fiscal Year: 2000
    The long-term objective of this project is to develop a novel active immunotherapy approach to inhibit tumor angiogenesis...
  41. Immunotherapy with TRICOM Modified Dendritic Cells
    Herbert Lyerly; Fiscal Year: 2002
    ..feasibility, and clinical and immunologic activity of this potent, novel and broadly applicable form of active immunotherapy- rF-CEA(6D)/TRICOM modified DC...
  42. Vaccine therapy of congenital adrenal Hyperplasia
    Scott Rivkees; Fiscal Year: 2003
    ..We also anticipate being able to extend this novel approach to the treatment of other receptor-mediated endocrine disorders, such as hyperthyroidism. ..
  43. Vector Mediated Vaccine Therapy of Cancer
    Wei Wei Zhang; Fiscal Year: 2004
    ....
  44. PSMA-KLH Conjugate Vaccines for Prostate Cancer
    Sofija Andjelic; Fiscal Year: 2004
    ..This unique pattern of expression makes PSMA a compelling target for active immunotherapy or vaccine development not only for prostate cancer, but also for other tumors...
  45. STRUCT-BASED DESIGN OF INHIBITORS FOR FLU NEURAMINIDASE
    Y Babu; Fiscal Year: 1991
    ..The long-term goal is to design and synthesize active-site inhibitors of neuraminidase which are effective and safe anti-viral agents against influenza in the human population...
  46. Custon Designing Peptides for Cancer Immunotherapy
    Douglas Lake; Fiscal Year: 2005
    DESCRIPTION (PROVIDED BY APPLICANT): Specific, active immunotherapy is an attractive approach for the treatment of cancer...
  47. DENDRITIC CELL MOBILIZATION AND ACTIVE IMMUNOTHERAPY
    Herbert Lyerly; Fiscal Year: 2005
    ....
  48. CO17 1A/GA733 ANTIGEN IN COLORECTAL CANCER THERAPY
    Dorothee Herlyn; Fiscal Year: 2002
    ..With the availability of cloned tumor antigens, new potentially improved approaches to active immunotherapy have become available...
  49. AMELIORATION OF RECURRENT HERPES KERATITIS
    PATRICK STUART; Fiscal Year: 2007
    ..Furthermore, these studies could possibly suggest more effective immunotherapies designed to ameliorate human HSK disease. ..
  50. DNA Tolerizing Vaccine Therapy for Multiple Sclerosis
    Hideki Garren; Fiscal Year: 2002
    ..S. FDA for the evaluation of a DNA tolerizing vaccine in a phase I clinical trial. ..
  51. HUMAN FOAMY VIRUS STRUCTURAL PROTEINS
    Paul Goepfert; Fiscal Year: 2000
    ..A better understanding of the human member of this remarkable but relatively neglected genus of retroviruses will enhance our knowledge of both viral and cellular mechanisms. ..
  52. DerG (a new immunomodulator) Treatment of Viral Encepha*
    KENNETH ROSENTHAL; Fiscal Year: 2005
    ....
  53. HU/SCID MOUSE MODEL: PREDICTING IMMUNOTHERAPY RESPONSES
    Heinz Kohler; Fiscal Year: 1990
    b>Active immunotherapy using anti-idiotypic antibodies which mimic tumor- associated antigens has been shown to be effective in animals and patients...
  54. Development of Survivin as a Vaccine Target for Pancreatic Cancer
    Laszlo Radvanyi; Fiscal Year: 2007
    ..A new and promising treatment for PC is active immunotherapy targeting over-expressed tumor-specific antigens with therapeutic cancer vaccines...
  55. Breaking tolerance to mEGP self-antigen
    Dorothee Herlyn; Fiscal Year: 2009
    ..The human gastrointestinal carcinoma-associatedAg GA733 (EpCAM) has been a suitable target for passive and active immunotherapy of these tumors in cancer patients...
  56. IMMUNE RESPONSE ANALYSIS OF IL-12/B71 MELANOMA VACCINES
    THERESA STRONG; Fiscal Year: 1999
    ..Recent studies employing active immunotherapy approaches for melanoma have begun to yield encouraging results...
  57. BD Biosciences LSR Flow Cytometer
    Richard Hardy; Fiscal Year: 2002
    ..abstract_text> ..
  58. Alphavirus prime-boost vaccines for prostate cancer
    Jason Gardner; Fiscal Year: 2003
    ..This pattern of expression makes PSMA a compelling target for active immunotherapy. Our overall goal is to develop and clinically evaluate PSMA-based vaccines...
  59. IMMUNE RESPONSES TO GENETICALLY MODIFIED TUMORS
    Alfred Chang; Fiscal Year: 1993
    ....
  60. Multimodality Therapy for Metastatic Breast Cancer
    Jonathan Serody; Fiscal Year: 2006
    ..The long-term goals of this work are to evaluate safe and effective therapies that induce a complete remission for the treatment of women with metastatic breast cancer. ..
  61. Development of PSMA -based recombinant protein vaccines
    Gerald Donovan; Fiscal Year: 2007
    ..For these reasons, PSMA represents a highly attractive target for active immunotherapy of prostate cancer...
  62. CEA BASED VACCINE THERAPY OF CEA BEARING TUMORS
    John Marshall; Fiscal Year: 1999
    ....
  63. IMMUNOTHERAPY WITH RENAL TUMOR RNA TRANSFECTED CELLS
    Johannes Vieweg; Fiscal Year: 2004
    ..An ongoing phase I clinical trial of active immunotherapy with DC transfected with RNA encoding a widely expressed tumor antigen, prostate specific antigen (PSA), ..
  64. Elimination of Regulatory T Cells
    Johannes Vieweg; Fiscal Year: 2004
    ..protocols can be dramatically enhanced by the elimination of CD25+ regulatory T cell subsets preceding active immunotherapy. Here we propose to perform a clinical trial administering mature, renal tumor RNA transfected DC to ..
  65. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2005
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..